Sales of emergency contraception are estimated to rise by around 10% in the US in the week after the New Year holiday, suggesting that this period is associated with increased risks of unprotected sex compared with other holidays, finds a study published in the Christmas issue of The BMJ.
FDA Withdraws Approval of FGFR Inhibitor for Bile Duct Cancer
The FDA has withdrawn the approval of infigratinib (Truseltiq) as a second-line treatment for metastatic cholangiocarcinoma at the request of the drugmaker, the agency announced
May 21, 2024